TLR-7 and -8 agonists as vaccine adjuvants

Expert Review of Vaccines

Volumn 10, Issue 4, 2011, Pages 405-407

  Tomai, Mark A ^a   Vasilakos, John P ^b  

^a 3M COMPANY   (United States)

^b Drug Delivery Systems Division   (United States)

Author keywords

adjuvant; imidazoquinoline; imiquimod; resiquimod; TLR 7; TLR 8; vaccine

Indexed keywords

3M 052; ALUMINUM POTASSIUM SULFATE; ANTIALLERGIC AGENT; CHEMOKINE; CYTOKINE; DNA VACCINE; HEPATITIS B VACCINE; IMIDAZOQUINOLINE DERIVATIVE; IMIQUIMOD; IMMUNOLOGICAL ADJUVANT; MIFAMURTIDE; MONTANIDE ISA 51; PEPTIDE VACCINE; PHOSPHORYL LIPID A; POLLEN VACCINE; POLLINEX; RESIQUIMOD; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 7 AGONIST; TOLL LIKE RECEPTOR 8 AGONIST; UNCLASSIFIED DRUG; WART VIRUS VACCINE;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTING CELL; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL MATURATION; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG FORMULATION; EDITORIAL; EMULSION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; NONHUMAN; PRIORITY JOURNAL; TH1 CELL; TH2 CELL; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; COMMUNICABLE DISEASE CONTROL; HUMANS; NEOPLASMS; TOLL-LIKE RECEPTOR 7; TOLL-LIKE RECEPTOR 8; VACCINES;

EID: 79955084311     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.11.26     Document Type: Editorial

References (22)

1. Singh M, Ugozzoli M, Kazzaz J et al. A preliminary evaluation of alternative adjuvants to alum using a range of established and new generation vaccine antigens. Vaccine 24(10), 1680-1686 (2006). (Pubitemid 43238245)
2. Ott G, Barchfeld GL, Chernoff D, Radhakrishnan R, van Hoogevest P, Van Nest G. MF59. Design and evaluation of a safe and potent adjuvant for human vaccines. Pharm. Biotechnol. 6, 277-296 (1995).
3. Diebold SS. Recognition of viral single-stranded RNA by Toll-like receptors. Adv. Drug Deliv. Rev. 60(7), 813-823 (2008).
4. Diebold SS, Massacrier C, Akira S, Paturel C, Morel Y, Reis e Sousa C. Nucleic acid agonists for Toll-like receptor 7 are defined by the presence of uridine ribonucleotides. Eur. J. Immunol. 36(12), 3256-3267 (2006). (Pubitemid 44932727)
5. Hemmi H, Kaisho T, Takeuchi O et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat. Immunol. 3(2), 196-200 (2002). (Pubitemid 34141451)
6. Jurk M, Heil F, Vollmer J et al. Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. Nat. Immunol. 3(6), 499 (2002). (Pubitemid 34669818)
7. Kaisho T, Akira S. Regulation of dendritic cell function through Toll-like receptors. Curr. Mol. Med. 3(4), 373-385 (2003). (Pubitemid 36621794)
8. Wysocka M, Newton S, Benoit BM et al. Synthetic imidazoquinolines potently and broadly activate the cellular immune response of patients with cutaneous T-cell lymphoma: synergy with interferon-g enhances production of interleukin-12. Clin. Lymphoma Myeloma 7(8), 524-534 (2007). (Pubitemid 350043490)
9. Miller RL, Meng TC, Tomai MA. The antiviral activity of Toll-like receptor 7 and 7/8 agonists. Drug News Perspect. 21(2), 69-87 (2008). (Pubitemid 351628232)
10. Ahonen CL, Gibson SJ, Smith RM et al. Dendritic cell maturation and subsequent enhanced T-cell stimulation induced with the novel synthetic immune response modifier R-848. Cell. Immunol. 197(1), 62-72 (1999).
11. Lore K, Betts MR, Brenchley JM et al. Toll-like receptor ligands modulate dendritic cells to augment cytomegalovirus-and HIV-1-specific T cell responses. J. Immunol. 171(8), 4320-4328 (2003). (Pubitemid 37238711)
12. Durand V, Wong SY, Tough DF, Le Bon A. Shaping of adaptive immune responses to soluble proteins by TLR agonists: a role for IFN-a/b. Immunol. Cell. Biol. 82(6), 596-602 (2004). (Pubitemid 39563960)
13. Ma R, Du JL, Huang J, Wu CY. Additive effects of CpG ODN and R-848 as adjuvants on augmenting immune responses to HBsAg vaccination. Biochem. Biophys. Res. Commun. 361(2), 537-542 (2007). (Pubitemid 47187279)
14. Vasilakos JP, Smith RM, Gibson SJ et al. Adjuvant activities of immune response modifier R-848: comparison with CpG ODN. Cell. Immunol. 204(1), 64-74 (2000).
15. Wille-Reece U, Wu CY, Flynn BJ, Kedl RM, Seder RA. Immunization with HIV-1 Gag protein conjugated to a TLR7/8 agonist results in the generation of HIV-1 Gag-specific Th1 and CD8+ T cell responses. J. Immunol. 174(12), 7676-7683 (2005). (Pubitemid 40806272)
16. Du J, Wu Z, Ren S et al. TLR8 agonists stimulate newly recruited monocyte-derived cells into potent APCs that enhance HBsAg immunogenicity. Vaccine 28(38), 6273-6281 (2010).
17. Otero M, Calarota SA, Felber B et al. Resiquimod is a modest adjuvant for HIV-1 Gag-based genetic immunization in a mouse model. Vaccine 22(13-14), 1782-1790 (2004). (Pubitemid 38455417)
18. Thomsen LL, Topley P, Daly MG, Brett SJ, Tite JP. Imiquimod and resiquimod in a mouse model: adjuvants for DNA vaccination by particle-mediated immunotherapeutic delivery. Vaccine 22(13-14), 1799-1809 (2004). (Pubitemid 38447228)
19. Weeratna RD, Makinen SR, McCluskie MJ, Davis HL. TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848).Vaccine 23(45), 5263-5270 (2005). (Pubitemid 41443432)
20. + T cell expansion with variable dependence on type I IFN. J. Exp. Med. 199(6), 775-784 (2004). (Pubitemid 38375197)
21. + T cell responses in nonhuman primates. Proc. Natl Acad. Med. USA 102(42), 15190-15194 (2005). (Pubitemid 41513357)
22. Wille-Reece U, Flynn BJ, Lore K et al. Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates. J. Exp. Med. 203(5), 1249-1258 (2006). (Pubitemid 43736594)